INmune Bio, Inc.
Price Action
Technical Summary
CONSOLIDATINGINmune Bio, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings growth of 53% provides fundamental context to the price action. However, price is extended 21% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.43 | +21.44% | ABOVE |
| 50 SMA | $1.43 | +21.48% | ABOVE |
| 100 SMA | $1.37 | +27.09% | ABOVE |
| 150 SMA | $1.48 | +17.69% | ABOVE |
| 200 SMA | $1.56 | +11.62% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is INMB in an uptrend right now?
INMB has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is INMB overbought or oversold?
INMB's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is INMB outperforming the market?
INMB has a Relative Strength (RS) Rating of 65 out of 99. INMB is performing about average compared to the market.
Where is INMB in its 52-week range?
INMB is trading at $1.74, which is 54% of its 52-week high ($3.24) and 30% above its 52-week low ($1.09).
How volatile is INMB?
INMB has a Beta of 2.64 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.